Abbott India Ltd
NSE: ABBOTINDIA BSE: 500488
₹26070
-225 (0.86%)
Thu, 22 Oct 2026, 09:47 pm
Market Cap (in Cr)55983.41
PE Ratio34.31
Dividend1.99
Health Technology
Pharmaceuticals: Major
24.5KAbbott India Ltd Company History
1944
- Issued all shares to Boots Pure Drug Co., Ltd.; 5 shares for cash.
1963
- Issued 200,000 shares to the company.
1965
- Incorporated on December 15 to manufacture Boots brand medical, pharmaceutical, agricultural, and animal health products.
- Commissioned plant with 1,500 mega units capacity in January.
- Commissioned sterile manufacturing unit for insulin in September.
- Entered technical collaboration with Boots Pure Drug Co. Ltd., England on October 19.
- Issued 200,000 shares to public at premium of Rs 13 per share in December.
1969
- Issued 25,000 shares at par to L.I.C., U.T.I., I.C.I.C.I. on 5% debenture conversion.
1971
- Changed name from Boots Pure Drug Co. (India) Ltd. effective November 1.
- Changed name to Boots Pharmaceuticals Ltd. effective January 1.
1973
- Issued 25,000 shares at par to L.I.C., U.T.I., I.C.I.C.I. on 5% debenture conversion.
1976
- Initiated chemical plant at Ahmednagar for Ibuprofen manufacture.
- Issued 775,000 bonus shares in 1:1 proportion.
1977
- Issued 148,150 right equity shares at premium of Rs 3.50 in 2:9 proportion.
1979
- Issued 266,050 bonus shares in 1:3 proportion.
1983
- Issued 170,000 15% non-convertible debentures of Rs 100 each, redeemed October 1990.
- Boots Company PLC disinvested 300,000 equity shares at premium of Rs 45.
- Issued 427,290 equity shares at premium of Rs 45 as rights.
- Reduced Boots Company PLC holding from 53% to 40%.
1984
- Issued 1,358,520 bonus equity shares in 3:5 proportion.
1986
- Applied for expansion to 200 tonnes Ibuprofen and 300 M.U. insulin.
- Offered 427,280 equity shares as rights at premium of Rs 45 per share.
1987
- Received letter of intent for Ibuprofen and insulin expansions.
- Implemented Ibuprofen expansion capacity.
- Applied for industrial license for Ranitidine Hydrochloride and formulations.
- Issued 4,050,000 bonus equity shares in 1:1 proportion.
1988
- Launched Advene and Froben.
- Initiated project for new formulation factory at Jejuri, Pune.
1989
- Launched Brufen Junior Syrup, Chota Strepsils Icy, Optrex Eye Lotion, Highly Purified Insulins, Nausidome.
1991
- Launched Human Insulins, Frozen SR, Optren Eye Drops.
1994
- Launched Novopen, Human Mixtard, Mixtard Penfills.
- Subsidiaries: Beem Healthcare Ltd., Lenbrook Pharmaceuticals Ltd., Valencia Pharmaceuticals Ltd.
1995
- Changed name to Knoll Pharmaceuticals Ltd. effective October 31.
1997
- Launched Clivarine anticoagulant.
- Acquired Epilex for Rs 9.90 crores.
- Commissioned new Goa plant.
- Lupharma GmbH made public offer for 11% stake.
- Entered co-marketing arrangement with SmithKline Beecham.
1998
- Launched Cremaffin anticoagulant low molecular weight heparin.
- Lupharma GmbH made public offer for 11% stake to reach 51%.
1999
- Merged Beem Healthcare effective July 1998.
- Entered pact with Torrent Pharmaceuticals and Novo Nordisk for human insulin.
2000
- Entered agreement with Kalpataru Homes for leasehold assignment.
- Ranbaxy Laboratories agreed to market brands in select overseas markets.
2001
- Lupharma UK Holding One Ltd. proposed to acquire 51% shares from Lupharma GmbH.
2002
- Changed name to Abbott India following takeover of BASF Pharma by Abbott Laboratories.
2003
- Mr. V. D. Narkar resigned as Director effective June 19.
- Appointed Mr. Ashok Dayal as Additional Director.
- Implemented scheme of amalgamation of Lenbrook Pharmaceuticals with the company.
2008
- Appointed Mr. Thomas Dee as Additional Director.
2009
- Recommended dividend of Rs 14 per share.
2010
- Recommended dividend of Rs 17 per share.
2011
- Recommended dividend of Rs 17 per share.
2012
- Recommended dividend of Rs 17 per share.
2013
- Named Multinational Pharmaceutical Company of the Year for third consecutive year at Frost & Sullivan Awards.
- Announced national hypothyroidism prevalence study results.
2014
- Launched thyroid awareness initiative in Uttar Pradesh and Uttarakhand with Indian Thyroid Society.
- Awarded Golden Peacock Innovation Management Award.
2021
- Launched Pandemic Defense Coalition.
- Launched Brufen Power spray.
- Launched device for treatment of premature babies and newborns with heart openings.
- Launched new Pediasure for catch-up growth in children.
2022
- Announced collaborations for holistic diabetes care.
- Launched Arachitol Gummies for Vitamin D and Calcium.
- Launched Grow Right 2.0 for child growth.
- Launched Ensure with HMB for muscle protection and strength.
- Launched Navitor TAVI system for aortic stenosis.
2023
- Launched Vertigo Coach app.
- Launched Pediasure with Nutri-Pull system.
- Launched vascular imaging platform powered by Ultreon 1.0 Software.
- Launched XIENCE Sierra Everolimus Eluting Coronary Stent System.
2024
- Launched next-generation Xience Sierra stent.
- Launched GLP systems Track automation solutions.
- Inaugurated innovative outreach centers with Yrgcare.
- Launched Aveir Vr leadless pacemaker system.
2025
- Launched new advanced formulation of Ensure Diabetes Care.
- Launched AVEIR dual chamber leadless pacemaker system.
- Introduced lab-based blood test to evaluate concussion.
- Launched next-gen Freestyle Libre 2 Plus with continuous glucose readings and alarms.
- Introduced Navitor Vision in India for aortic stenosis.
